Life insurance underwriting for cancer survivors is one of the most variable areas in the industry. A cancer history does not automatically mean uninsurable — in many cases it means "insurable with more information and potentially a longer waiting period." The outcome depends almost entirely on the type of cancer, its stage at diagnosis, the treatment received, time in remission, and your current health status. Two cancer survivors applying for life insurance in Florida may receive identical rates or wildly different offers depending on their specific diagnoses.
This guide walks through how life insurance carriers evaluate cancer history in Florida, which cancers tend to be most and least favorable in underwriting, and what your realistic options are at different points in remission.
When a carrier receives an application disclosing a cancer history, the underwriter requests an Attending Physician Statement (APS) from the treating oncologist covering:
| Cancer Type | Stage / Type | Typical Waiting Period | Typical Underwriting Outcome |
|---|---|---|---|
| Basal cell carcinoma (skin) | Any — no metastasis | 1 year post-treatment | Standard or better; rarely affects rating |
| Squamous cell carcinoma (skin) | Localized, no spread | 1–2 years | Standard to Standard Plus |
| In-situ carcinoma (Stage 0 — breast, cervix, colon) | Stage 0 | 1–2 years | Standard or near-standard |
| Breast cancer | Stage I | 2–3 years post-treatment | Standard to Table 2 |
| Breast cancer | Stage II | 3–5 years post-treatment | Table 2–4 |
| Breast cancer | Stage III | 5–10 years post-treatment | Table 4–8 or decline during waiting period |
| Prostate cancer | Low-risk (Gleason ≤6) | 2 years post-treatment or watchful waiting | Standard to Table 2 |
| Prostate cancer | Intermediate-risk (Gleason 7) | 3–5 years | Table 2–4 |
| Prostate cancer | High-risk (Gleason 8–10) | 5–10 years | Table 4–8 or decline |
| Thyroid cancer (papillary/follicular) | Stage I–II | 1–3 years | Standard to Table 2 (highly treatable) |
| Colon cancer | Stage I | 2–3 years | Standard to Table 2 |
| Colon cancer | Stage II–III | 5 years | Table 2–6 |
| Melanoma | Stage I (in-situ or thin) | 2–3 years | Standard to Table 2 |
| Melanoma | Stage II–III | 5–10 years | Table 4–8 or decline |
| Non-Hodgkin's lymphoma | Low-grade in remission | 5 years | Table 4–6 |
| Hodgkin's lymphoma | Stage I–II, complete remission | 5 years | Table 2–4 after 5 years |
| Leukemia (CLL, low risk) | Early stage, stable | 5–10 years | Table 4–8 |
| Pancreatic cancer | Any | 10+ years if any offer is made | Typically decline; guaranteed issue best option |
| Lung cancer | Stage I (resected) | 5 years | Table 4–8 depending on cell type |
| Liver / bile duct cancer | Any | 10+ years | Typically decline during standard window |
For most cancer types, the probability of recurrence is highest in the first several years after treatment. As years pass without recurrence, the statistical risk of the cancer returning declines, which is why underwriters extend better offers to applicants who are further from their last treatment. This is sometimes called the "seasoning" period — the longer your remission is documented, the better your underwriting outcome.
The exception is cancers with very late recurrence patterns — breast cancer, for example, can recur 10 or more years after the original diagnosis, which is why carriers use longer waiting periods for higher-stage breast cancer than for cancers with shorter recurrence windows. Melanoma also has a known late-recurrence pattern that influences how long carriers want to see documented remission before offering standard rates.
Basal cell carcinoma and localized squamous cell carcinoma of the skin are among the most common cancers in Florida — sun exposure is a major risk factor — and also the most insurable. Basal cell carcinoma, in particular, rarely metastasizes and is almost always cured by local excision. Most carriers will offer standard rates to applicants with a basal cell carcinoma history after 1 year from treatment, sometimes sooner. Squamous cell carcinoma of the skin without lymph node involvement is similarly treated in most underwriting guidelines.
Applicants often assume their skin cancer diagnosis will significantly affect their rates — for basal cell and localized squamous cell cases, it typically does not once the appropriate waiting period has passed.
Florida has a significant population of breast cancer survivors, and the question of life insurance after breast cancer comes up frequently. The underwriting outcome depends heavily on the stage and receptor status of the tumor:
For Florida residents within a few years of treatment for an aggressive cancer — or with cancer types that are rarely insurable through traditional underwriting — guaranteed issue life insurance provides the only realistic path to coverage. It requires no medical questions, accepts all applicants in the eligible age range (45–85 for most carriers), and provides coverage amounts of $5,000 to $25,000.
The limitations are significant: the graded benefit period means that non-accidental deaths in the first 2–3 years result in only a return of premiums, not the full face amount. After the graded period, the full benefit is payable. For Florida cancer survivors whose primary concern is covering final expenses and not leaving a financial burden on their family, guaranteed issue fulfills that role. Additional resources for Florida insurance planning are available at Sunstate Coverage.
Every cancer history is different. Work with a licensed Florida agent who understands impaired-risk underwriting to find your best available option.
Get a Life Insurance Quote After CancerGenerally, no. Most traditional life insurance carriers will not issue a new policy to someone currently undergoing active cancer treatment — chemotherapy, radiation, immunotherapy, or surgery for an active malignancy. The application will typically be postponed until treatment is completed and the applicant has achieved documented remission. Guaranteed issue life insurance is the only option for coverage during active treatment, and even some guaranteed issue carriers exclude active cancer.
The waiting period depends on the cancer type, stage, and treatment. For low-risk cancers like basal cell skin cancer or in-situ carcinoma, standard rates may be possible after 1–2 years. For moderate-risk cancers like early-stage breast cancer or early-stage prostate cancer, carriers typically want 2–5 years in remission. For high-risk or aggressive cancers — stage III–IV solid tumors, leukemia, lymphoma, sarcoma — waiting periods of 5–10 years in complete remission are common before standard underwriting offers are possible.
Both matter, but cancer type carries significant independent weight. Two patients who both had Stage 1 cancer — one basal cell carcinoma of the skin, one pancreatic cancer — will face dramatically different underwriting outcomes. Basal cell skin cancer is one of the most insurable cancer histories in the industry. Pancreatic cancer, even at Stage 1, results in a long waiting period (often 10+ years) or declination because of its high recurrence and mortality rates. The cancer's biology and prognosis drives much of the underwriting logic.
If subsequent evaluation confirmed that you do not have cancer — for example, a biopsy initially suspected malignancy but pathology confirmed benign tissue — you should disclose the full history on the application including the original finding and the subsequent negative confirmation. Carriers will review the documentation and, if the evidence clearly shows a benign finding, the matter should not result in a cancer-based rating. Accurate and complete disclosure with supporting documentation is essential in these situations.